These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 21959979)
1. Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma. Lee EM; Rha SY; Lee J; Park KH; Ahn JH Cancer Chemother Pharmacol; 2012 Mar; 69(3):635-42. PubMed ID: 21959979 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma]. Yao Z; Yang S; Zhao Y; Yao S; Guo H; Liu Y Zhonghua Zhong Liu Za Zhi; 2014 Jul; 36(7):541-5. PubMed ID: 25327662 [TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Seddon B; Strauss SJ; Whelan J; Leahy M; Woll PJ; Cowie F; Rothermundt C; Wood Z; Benson C; Ali N; Marples M; Veal GJ; Jamieson D; Küver K; Tirabosco R; Forsyth S; Nash S; Dehbi HM; Beare S Lancet Oncol; 2017 Oct; 18(10):1397-1410. PubMed ID: 28882536 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis. Takahashi M; Komine K; Imai H; Okada Y; Saijo K; Takahashi M; Shirota H; Ohori H; Takahashi S; Chiba N; Mori T; Shimodaira H; Ishioka C PLoS One; 2017; 12(5):e0176972. PubMed ID: 28489919 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma. Kaya AO; Büyükberber S; Ozkan M; Alkiş N; Sevinc A; Ozdemir NY; Alici S; Esbah O; Berk V; Camci C; Ulas A; Coskun U; Benekli M; Asian Pac J Cancer Prev; 2012; 13(2):463-7. PubMed ID: 22524807 [TBL] [Abstract][Full Text] [Related]
7. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736 [TBL] [Abstract][Full Text] [Related]
8. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Verschraegen CF; Arias-Pulido H; Lee SJ; Movva S; Cerilli LA; Eberhardt S; Schmit B; Quinn R; Muller CY; Rabinowitz I; Purdy M; Snyder D; Bocklage T Ann Oncol; 2012 Mar; 23(3):785-790. PubMed ID: 21746804 [TBL] [Abstract][Full Text] [Related]
9. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. Lee MY; Jung KS; Kim HS; Lee JY; Lim SH; Kim M; Jung HA; Kim SM; Sun JM; Ahn MJ; Lee J; Park SH; Yi SY; Hwang IG; Lee SC; Ahn HK; Lim DH; Lee SI; Park KW World J Gastroenterol; 2015 Apr; 21(14):4268-74. PubMed ID: 25892878 [TBL] [Abstract][Full Text] [Related]
10. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study. Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S Oncology; 2002; 62(1):33-8. PubMed ID: 11810041 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. García-Del-Muro X; López-Pousa A; Maurel J; Martín J; Martínez-Trufero J; Casado A; Gómez-España A; Fra J; Cruz J; Poveda A; Meana A; Pericay C; Cubedo R; Rubió J; De Juan A; Laínez N; Carrasco JA; de Andrés R; Buesa JM; J Clin Oncol; 2011 Jun; 29(18):2528-33. PubMed ID: 21606430 [TBL] [Abstract][Full Text] [Related]
13. Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients. Tanaka K; Joyama S; Chuman H; Hiraga H; Morioka H; Yoshikawa H; Hosaka M; Takahashi M; Kubo T; Hatano H; Kaya M; Toguchida J; Nishida Y; Nagano A; Tsumura H; Iwamoto Y World J Surg Oncol; 2016 Dec; 14(1):306. PubMed ID: 27931230 [TBL] [Abstract][Full Text] [Related]
14. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. Boukovinas I; Androulakis N; Vamvakas L; Papakotoulas P; Ziras N; Polyzos A; Kalykaki A; Kotsakis A; Xenidis N; Gioulmbasanis I; Mavroudis D; Georgoulias V Ann Oncol; 2006 Nov; 17(11):1687-92. PubMed ID: 16968872 [TBL] [Abstract][Full Text] [Related]
15. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Boukovinas I; Androulakis N; Kentepozidis N; Polyzos A; Papakotoulas P; Ziras N; Kotsakis A; Vardakis N; Karampeazis A; Markos V; Kostakopoulos A; Constantinides CA; Samonis G; Mavroudis D; Georgoulias V Cancer Chemother Pharmacol; 2012 Feb; 69(2):351-6. PubMed ID: 21748359 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status. Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. Qi WX; He AN; Tang LN; Shen Z; Lin F; Yao Y Jpn J Clin Oncol; 2012 May; 42(5):427-31. PubMed ID: 22450929 [TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer. Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958 [TBL] [Abstract][Full Text] [Related]
20. Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. Ebeling P; Eisele L; Schuett P; Bauer S; Schuette J; Moritz T; Seeber S; Flasshove M Onkologie; 2008 Feb; 31(1-2):11-6. PubMed ID: 18268394 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]